Phase II study of a PARP inhibitor, talazoparib, in HER2-metastatic breast cancer with a somatic BRCA1/2 mutation present in cell-free DNA or tumor tissue genotyping

被引：0
|
作者：
Vidula, Neelima
Damodaran, Senthil
Bhave, Manali
Rugo, Hope
Shah, Ami N.
Blouch, Erica
Ruffle-Deignan, Nathan Royce
Ogbenna, Ogadinma
Flaum, Lisa E.
Cristofanilli, Massimo
Sparano, Joseph
Ostrer, Harry
Abramson, Vandana
Horick, Nora
Bardia, Aditya
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO4-19-06
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO4-19-06
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Phase I study of the PARP inhibitor olaparib (O) in combination with carboplatin (C) in BRCA1/2 mutation carriers with breast (Br) or ovarian (Ov) cancer (Ca).
    Lee, J.
    Annunziata, C. M.
    Minasian, L. M.
    Zujewski, J.
    Prindiville, S. A.
    Kotz, H. L.
    Squires, J.
    Houston, N. D.
    Ji, J. J.
    Yu, M.
    Doroshow, J. H.
    Kohn, E. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [32] Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study
    Litton, Jennifer K.
    Beck, J. Thaddeus
    Jones, Jason M.
    Andersen, Jay
    Blum, Joanne L.
    Mina, Lida A.
    Brig, Raymond
    Danso, Michael
    Yuan, Yuan
    Abbattista, Antonello
    Noonan, Kay
    Niyazov, Alexander
    Chakrabarti, Jayeta
    Czibere, Akos
    Symmans, William F.
    Telli, Melinda L.
    ONCOLOGIST, 2023, 28 (10): : 845 - 855
  • [33] A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes
    Joshua J. Gruber
    Anosheh Afghahi
    Kirsten Timms
    Alyssa DeWees
    Wyatt Gross
    Vasily N. Aushev
    Hsin-Ta Wu
    Mustafa Balcioglu
    Himanshu Sethi
    Danika Scott
    Jessica Foran
    Alex McMillan
    James M. Ford
    Melinda L. Telli
    Nature Cancer, 2022, 3 : 1181 - 1191
  • [34] Serial circulating tumor DNA from patients with metastatic breast cancer with and without BRCA1/2 mutations
    Collier, Katharine A.
    Tallman, David
    Weber, Zachary T.
    Haynam, Marcy
    Adams, Elizabeth J.
    Jenison, Janet
    Asad, Sarah
    Lustberg, Maryam
    Cherian, Mathew
    Ramaswamy, Bhuvaneswari
    Sardesai, Sagar
    Williams, Nicole
    Wesolowski, Robert
    Vandeusen, Jeffrey
    Gatti-Mays, Margaret E.
    Pariser, Ashley
    Mortazavi, Amir
    Stover, Daniel G.
    CANCER RESEARCH, 2022, 82 (04)
  • [35] A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA)
    Litton, J.
    Ettl, J.
    Hurvitz, S. A.
    Mina, L. A.
    Rugo, H. S.
    Lee, K-H
    Yerushalmi, R.
    Woodward, N.
    Goncalves, A.
    Moreno, F.
    Roche, H.
    Im, Y-H
    Martin, M.
    Bhattacharya, S.
    Peterson, A.
    Hannah, A.
    Eiermann, W.
    Blum, J.
    CANCER RESEARCH, 2017, 77
  • [36] A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO)
    Turner, Nicholas C.
    Telli, Melinda L.
    Rugo, Hope S.
    Mailliez, Audrey
    Ettl, Johannes
    Grischke, Eva-Maria
    Mina, Lida A.
    Balmana, Judith
    Fasching, Peter A.
    Hurvitz, Sara A.
    Wardley, Andrew M.
    Chappey, Colombe
    Hannah, Alison L.
    Robson, Mark E.
    CLINICAL CANCER RESEARCH, 2019, 25 (09) : 2717 - 2724
  • [37] Prognostic significance of BRCA1 and BRCA2 methylation status in circulating cell-free DNA of Pancreatic Cancer patients
    Koukaki, Triantafyllia
    Balgkouranidou, Ioanna
    Biziota, Eirini
    Karayiannakis, Anastasios
    Bolanaki, Helen
    Karamitrousis, Evangelos
    Zarogoulidis, Paul
    Deftereos, Savas
    Charalampidis, Charalampos
    Ioannidis, Aris
    Matthaios, Dimitrios
    Amarantidis, Kyriakos
    Kakolyris, Stylianos
    JOURNAL OF CANCER, 2024, 15 (09): : 2573 - 2579
  • [38] Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations
    Jing Xu
    Tanya E. Keenan
    Beth Overmoyer
    Nadine M. Tung
    Rebecca S. Gelman
    Karleen Habin
    Judy E. Garber
    Leif W. Ellisen
    Eric P. Winer
    Paul E. Goss
    Beow Y. Yeap
    Bruce A. Chabner
    Steven J. Isakoff
    Breast Cancer Research and Treatment, 2021, 189 : 641 - 651
  • [39] Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations
    Xu, Jing
    Keenan, Tanya E.
    Overmoyer, Beth
    Tung, Nadine M.
    Gelman, Rebecca S.
    Habin, Karleen
    Garber, Judy E.
    Ellisen, Leif W.
    Winer, Eric P.
    Goss, Paul E.
    Yeap, Beow Y.
    Chabner, Bruce A.
    Isakoff, Steven J.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 189 (03) : 641 - 651
  • [40] Fuzuloparib with or without apatinib in HER2-metastatic breast cancer (mBC) patients (pts) with germline BRCA1/2 mutations (gBRCA1/2m): A randomized phase III trial
    Li, H.
    Liu, J.
    Liu, Y.
    Ouyang, Q.
    Wang, S.
    Tong, Z.
    Teng, Y.
    Sun, T.
    Wang, X.
    Cheng, J.
    Zhou, X.
    Fanfan, L.
    Yan, M.
    Nie, J.
    Ye, C.
    Shao, Z-M.
    Wang, Y.
    Yang, X.
    Song, E.
    ANNALS OF ONCOLOGY, 2024, 35 (06) : 574 - 575
12345